Full Breakdown
A Singular Clinical Trial Targets the Ultra-Rare Jansen’s Disease
8/18/2026, 2:00:37 AM
Core Event: First-in-Human Study of an Experimental Therapy
Neena Nizar, a 3-foot-9-inch-tall woman with severe skeletal deformities caused by Jansen’s disease, spent ten weeks this summer as the sole participant in a National Institutes of Health (NIH) study of an experimental drug. The trial, designed to assess safety and dosing, was possible only because Nizar agreed to serve as a case study; without her involvement, the study would not have proceeded.
Background: The Rarity and Research Gap of Jansen’s Disease
Jansen’s disease is an ultra-rare genetic disorder; only about 30 individuals worldwide are known to have it, three of whom are Nizar and her two sons. Dr. Matthew Porteus, president of the American Society for Cell and Gene Therapy and director of Stanford’s Center for Definitive and Curative Medicine, notes that there are an estimated 6,000–10,000 rare diseases overall. Developing a drug for any single rare condition typically costs millions of dollars, and success depends on patient advocates locating manufacturers and clinicians willing to conduct trials.
Participant Profile and Trial Design
Nizar uses a wheelchair and experiences constant pain due to curved arm bones, ribs, neck, and skull. Although the experimental therapy is not expected to reverse her existing bone deformities, researchers hope that if the drug proves safe and biologically active, subsequent participants—potentially children with the same mutation—could receive treatment before irreversible skeletal changes occur.
Challenges in Translating Promising Research into Therapies
The case underscores the “herculean” effort required to attract attention and funding for diseases with a market too small to entice commercial development. Even with NIH support, the pathway from laboratory discovery to an approved medication remains fraught with financial and logistical obstacles, especially when patient populations number in the single digits.
Outlook: Potential Benefits for Future Patients
If the trial demonstrates favorable results, it could pave the way for pediatric enrollment, offering a chance to prevent the debilitating effects that have already manifested in adult patients like Nizar. The study therefore serves as both a scientific milestone and a cautionary illustration of the systemic barriers confronting ultra-rare disease drug development.
